Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CTSE | P14091 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066257 | 1.00 | KMT2A (0.46) | KMT2AHPGDMEN1RECQLKDM1A | |
| SCHEMBL4066265 | 1.00 | KMT2A (0.46) | KMT2AHPGDMEN1RECQLKDM1A | |
| SCHEMBL23153407 | 0.82 | KMT2A (0.53) | KMT2AHPGDKDM1AMAOBHDAC4 | |
| SCHEMBL765249 | 0.82 | KMT2A (0.53) | KMT2AHPGDKDM1AMAOBHDAC4 | |
| SCHEMBL28377071 | 0.82 | HDAC4 (0.47) | KMT2AKDM1AMAOBHDAC4HDAC6 | |
| SCHEMBL4083289 | 0.82 | KMT2A (0.53) | KMT2AHPGDKDM1AMAOBHDAC4 | |
| SCHEMBL6915186 | 0.80 | GRM5 (0.52) | KMT2AKDM1AMAOBHDAC4HDAC6 | |
| SCHEMBL15456460 | 0.80 | MAOA (0.62) | KMT2AHPGDMEN1RECQLKDM1A | |
| SCHEMBL13276199 | 0.80 | MAOA (0.62) | KMT2AHPGDMEN1RECQLKDM1A | |
| SCHEMBL13276465 | 0.80 | MAOA (0.62) | KMT2AHPGDMEN1RECQLKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | KMT2A 4522/4885HPGD 407/4885MEN1 4289/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | KMT2A 4512/4885HPGD 532/4885MEN1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.